Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 24(28): 3071-3089, 2018 Jul 28.
Article in English | MEDLINE | ID: mdl-30065554

ABSTRACT

Helicobacter pylori (H. pylori) is present in roughly 50% of the human population worldwide and infection levels reach over 70% in developing countries. The infection has classically been associated with different gastro-intestinal diseases, but also with extra gastric diseases. Despite such associations, the bacterium frequently persists in the human host without inducing disease, and it has been suggested that H. pylori may also play a beneficial role in health. To understand how H. pylori can produce such diverse effects in the human host, several studies have focused on understanding the local and systemic effects triggered by this bacterium. One of the main mechanisms by which H. pylori is thought to damage the host is by inducing local and systemic inflammation. However, more recently, studies are beginning to focus on the effects of H. pylori and its metabolism on the gastric and intestinal microbiome. The objective of this review is to discuss how H. pylori has co-evolved with humans, how H. pylori presence is associated with positive and negative effects in human health and how inflammation and/or changes in the microbiome are associated with the observed outcomes.


Subject(s)
Gastrointestinal Microbiome/physiology , Helicobacter Infections/physiopathology , Helicobacter pylori/physiology , Host-Pathogen Interactions/physiology , Inflammation/physiopathology , Biological Coevolution/physiology , Gastric Mucosa/microbiology , Gastric Mucosa/physiopathology , Helicobacter Infections/epidemiology , Helicobacter Infections/microbiology , Helicobacter pylori/pathogenicity , Humans , Inflammation/microbiology
2.
Cancer Lett ; 372(1): 10-23, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26718258

ABSTRACT

Malignant melanoma represents the fastest growing public health risk of all cancer types worldwide. Several strategies and anti-cancer drugs have been used in an effort to improve treatments, but the development of resistance to anti-neoplastic drugs remains the major cause of chemotherapy failure in melanomas. Previously, we showed that the sesquiterpene lactone, dehydroleucodine (DhL), promotes the accumulation of DNA damage markers, such as H2AX and 53BP1, in human tumor cells. Also DhL was shown to trigger either cell senescence or apoptosis in a concentration-dependent manner in HeLa and MCF7 cells. Here, we evaluated the effects of DhL on B16F0 mouse melanoma cells in vitro and in a pre-clinical melanoma model. DhL inhibited the proliferation of B16F0 cells by inducing senescence or apoptosis in a concentration-dependent manner. Also, DhL reduced the expression of the cell cycle proteins cyclin D1 and B1 and the inhibitor of apoptosis protein, survivin. In melanomas generated by subcutaneous injection of B16F0 cells into C57/BL6 mice, the treatment with 20 mg DhL /Kg/day in preventive, simultaneous and therapeutic protocols reduced tumor volumes by 70%, 60% and 50%, respectively. DhL treatments reduced the number of proliferating, while increasing the number of senescent and apoptotic tumor cells. To estimate the long-term effects of DhL, a mathematical model was applied to fit experimental data. Extrapolation beyond experimental time points revealed that DhL administration following preventive and therapeutic protocols is predicted to be more effective than simultaneous treatments with DhL in restricting tumor growth.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cellular Senescence/drug effects , Lactones/pharmacology , Melanoma, Experimental/drug therapy , Sesquiterpenes/pharmacology , Tumor Burden/drug effects , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin B1/metabolism , Cyclin D1/metabolism , Dose-Response Relationship, Drug , Female , Inhibitor of Apoptosis Proteins/metabolism , Male , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Models, Biological , Repressor Proteins/metabolism , Signal Transduction/drug effects , Survivin , Time Factors
3.
World J Gastroenterol ; 21(45): 12742-56, 2015 Dec 07.
Article in English | MEDLINE | ID: mdl-26668499

ABSTRACT

The sequence of events associated with the development of gastric cancer has been described as "the gastric precancerous cascade". This cascade is a dynamic process that includes lesions, such as atrophic gastritis, intestinal metaplasia and dysplasia. According to this model, Helicobacter pylori (H. pylori) infection targets the normal gastric mucosa causing non-atrophic gastritis, an initiating lesion that can be cured by clearing H. pylori with antibiotics or that may then linger in the case of chronic infection and progress to atrophic gastritis. The presence of virulence factors in the infecting H. pylori drives the carcinogenesis process. Independent epidemiological and animal studies have confirmed the sequential progression of these precancerous lesions. Particularly long-term follow-up studies estimated a risk of 0.1% for atrophic gastritis/intestinal metaplasia and 6% in case of dysplasia for the long-term development of gastric cancer. With this in mind, a better understanding of the genetic and epigenetic changes associated with progression of the cascade is critical in determining the risk of gastric cancer associated with H. pylori infection. In this review, we will summarize some of the most relevant mechanisms and focus predominantly but not exclusively on the discussion of gene promoter methylation and miRNAs in this context.


Subject(s)
Epigenesis, Genetic , Gastric Mucosa/microbiology , Gastritis/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/pathogenicity , Precancerous Conditions/microbiology , Stomach Neoplasms/metabolism , Animals , Bacterial Proteins/metabolism , Cell Cycle Proteins/genetics , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , DNA Damage , DNA Methylation , Gastric Mucosa/pathology , Gastritis/diagnosis , Gastritis/genetics , Gene Expression Regulation, Neoplastic , Glycoproteins/genetics , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter Infections/genetics , Helicobacter pylori/enzymology , Host-Pathogen Interactions , Humans , MicroRNAs/genetics , Precancerous Conditions/diagnosis , Precancerous Conditions/genetics , Stomach Neoplasms/diagnosis , Stomach Neoplasms/genetics , Virulence , gamma-Glutamylcyclotransferase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...